Cancer, Conflict and Global Health

Joined May 2015
135 Photos and videos
Richard Sullivan retweeted
An engaging #ASCO26 session: A Workforce Crisis—A Lancet Oncology Commission Authors @hedvighricak, @QUBCancerProf, @SullivanProf, @sudhasdc, @m_mutebi, @Dra_CVillarreal, @WilNgwa Missed the session? 📽️ Watch: youtu.be/VYr2Bjmxyhg & 📖 Read: thelancet.com/commissions-do…
8
17
6,544
A final word on GRAiL in JAMA - promise, hype and reality - academia.edu/167998188/Multi… @ASCO @myESMO
1
2
4
552
Richard Sullivan retweeted
Addressing the “Intellectual Wastelands” of Global Cancer Policy - Richard Sullivan @SullivanProf oncodaily.com/voices/richard… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedTwitter
1
4
146
Richard Sullivan retweeted
While civilian injuries in the the Middle East have been widely documented, little is known about civilian trauma pathways. Read our latest in @GlobalHealthBMJ with @GhassanAbuSitt1, @abdulsaterz, @SullivanProf, @gmbowsher, @thewarspace among others. gh.bmj.com/content/11/5/e021…
15
28
3,281
Richard Sullivan retweeted
Quite simply, a brilliantly written review on Chinese Pharma - From 2015 to 2024, over 393 cancer medicines were approved worldwide, 72 were China's branded new medicines. eg; zanubrut, tisleliz, avaprit, toripali, fruquin. @SullivanProf @kjmeetswrld ascopubs.org/doi/10.1200/GO-…
12
37
3,727
Richard Sullivan retweeted
What are the immediate and long-term implications of war for cancer care? Our editorial in @bmjoncology explores this question through lessons from Ukraine. With @gmbowsher, @SullivanProf, and Kateryna Denysenko: bmjoncology.bmj.com/content/…
1
5
13
709
Richard Sullivan retweeted
Our new article about @WHO essential cancer medicines published today in JAMA Oncology with @SullivanProf We ask: how to implement these medicines? jamanetwork.com/journals/jam…
1
9
301
Final report from cancer conference organised by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, held in Vatican City in 2025 pubmed.ncbi.nlm.nih.gov/4139…
4
187
Disparity in affordability across targeted and Immune-therapy cancer medicines used in the treatment of Head and Neck cancer doi.org/10.1002/hed.70212
3
201
Richard Sullivan retweeted
New Correspondence in @TheLancet Cancer medicines remain absent from global access metrics. #accesstomedicines #globaloncology @SullivanProf @LSEHealthPolicy @KingsCollegeLon
3
13
807
The stark realities of healthcare for displaced people. As conflict's worsen so too does the problem. Yet we are seeing societal attitudes worsen and protection increasingly eroded. thelancet.com/journals/lance…

1
1
2
174
Richard Sullivan retweeted
Important work by @DavidiTawfiles & our team in @TheLancet: "#Health #equity and displaced people: challenges, progress, and the path forward." 🌍🌎🌏This #InternationalMigrantsDay, heath of those most vulnerable should be a global priority 🔗 thelancet.com/journals/lance…
With #InternationalMigrantDay tomorrow, I’m honored to share our latest in @TheLancet “Health equity and displaced people: challenges, progress, and the path forward.” thelancet.com/journals/lance… Grateful to our team for their insight and commitment to the health of displaced.
1
4
8
959
Richard Sullivan retweeted
We're excited to be hosting this @LGCW2025 event with @KingsCollegeLon hosted by Richard @SullivanProf today! 🌟🙌👇 Check out the details below and join us online - or look out for the recording which will be shared on the event page and via our channels soon 📽️🗓️
How can we make cancer care in England both equitable and sustainable for the NHS? 🤔 Join researchers, patient advocates & experts for The Great Debate. This event is part of @LGCW2025, co-hosted ICON & the Institute of Cancer Policy @KingsCollegeLon 👉 bit.ly/43eRxiY
1
2
286
Global health, security and war and cancer across SSA. wiley.com/en-us/Handbook of …
3
186
New insights from Access Cancer Care India program (accesscancercare.in/) - the poverty of national cancer plan implimentation. See doi:10.1136/ bmjopen-2025-10875 @WHO

2
131
Op ed led by Dr Steven Bradley examining how a new England National Cancer Plan could and should embrace wider vision of innovation doi.org/10.1136/bmj.r2263

1
116